Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 552 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 Female Representation at the Top of the Oncology Field Has Hit... October 20, 2021 Load more HOT NEWS Being Diagnosed With a Childhood Cancer As an Adult Led Me... Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper New Research Looks for More Effective Breast Cancer Treatments for Black... Veteran Drops To The Ground When He Hears How Much His...
